Abiomed Inc (ABMD): David M Weber , Chief Operating Officer of Abiomed Inc sold 5,604 shares on May 16, 2016. The Insider selling transaction was reported by the company on May 17, 2016 to the Securities and Exchange Commission. The shares were sold at $94.66 per share for a total value of $529,901.25 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on May 9, 2016, David M Weber (Chief Operating Officer) sold 2,145 shares at $93.82 per share price.On May 9, 2016, Paul Thomas (director) sold 7,500 shares at $95.44 per share price.Also, On Apr 20, 2016, Dorothy E Puhy (director) sold 10,000 shares at $100.00 per share price.On Apr 20, 2016, Andrew J Greenfield (VP Healthcare Solutions) sold 10,000 shares at $99.10 per share price.
ABIOMED: On Monday, May 16, 2016 heightened volatility was witnessed in ABIOMED which led to swings in the share price. The shares opened for trading at $94.44 and hit $97.22 on the upside , eventually ending the session at $96.42, with a gain of 2.49% or 2.34 points. The heightened volatility saw the trading volume jump to 4,66,820 shares. The 52-week high of the share price is $110.6758 and the company has a market cap of $4,092 M . The 52-week low of the share price is at $59.04.
Abiomed Inc. is a provider of temporary percutaneous mechanical circulatory support devices. The Company offers care to heart failure patients. The Company’s products include Impella 2.5 a percutaneous micro heart pump with an integrated motor and sensors; Impella CP which is primarily used by either interventional cardiologists to support patients in the catheter lab or by surgeons in the heart surgery suite; Impella 5.0 and Impella LD a percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite; Impella RP a percutaneous catheter-based axial flow pump that is designed to allow greater than four liters of flow per minute; AB5000 a circulatory support system for the temporary support of acute heart failure patients in profound shock and Symphony a minimally invasive implantable cardiac assist device.